The board of directors of the Company approved removal of the noncompete clause for managers.

Published Date:2024-02-29

Original Link:https://www.onenessbio.com/en/news_detail273_4.htm

Statement
No	7	Date of announcement	2024/02/29	Time of announcement	17:42:49
Subject	The board of directors of the Company approved removal of the noncompete clause for managers.
To which item it meets	paragraph 21			Date of events	2024/02/29
Date of the board of directors resolution: 2024/02/29 Name and title of the managerial officer with permission to engage in competitive conduct: The general manager, Shu-ling Cheng. Items of competitive conduct in which the officer is permitted to engage: (1) Director of the Stemcyte TAIWAN CO., LTD.(Representative Director of the Diamond Biofund Inc.) (2) Director of the StemCyte International Ltd.(Representative Director of the Diamond Biofund Inc.) (3) Director of the ImmunAdd Inc.(Representative Director of the Diamond Biofund Inc.) Period of permission to engage in the competitive conduct: For the duration of employment as a manager of the Company. Circumstances of the resolution (please describe the results of voting in accordance with Article 32 of the Company Act): The board of directors approved the proposal unanimously with no changes. If the permitted competitive conduct belongs to the operator of a mainland China enterprise, the name and title of the managerial officer (if it is not the operator of a mainland China enterprise, please enter “N/A” below): N/A Company name of the mainland China enterprise and the officer’s position in the enterprise: N/A Address of the mainland China enterprise: N/A Operations of the mainland China enterprise: N/A Impact on the company’s finance and business: N/A If the managerial officer or director has invested in the mainland China enterprise, the monetary amount of the investment and the officer or director’s shareholding ratio: N/A Any other matters that need to be specified: None.